For the fourth quarter of 2008, total revenues were $4.34 million, compared to $1.78 million in the same quarter of 2007.
For 2008, total revenues were $14.97 million, compared to $1.78 million in 2007. For the 12 months ended December 31, 2008, net loss was $39.35 million compared to $41.17 million in 2007.
John Crowley, president and CEO of Amicus, said: “In 2008, we made great strides in advancing our lead clinical development programs for Fabry, Gaucher and Pompe diseases while maintaining a strong financial position.
“We plan to continue this momentum and believe 2009 will be a transformational year for Amicus, as we are committed to achieving several key milestones and to transitioning into a late-stage biopharmaceutical company.”